MLN8237 in Head and Neck Cancer

NCT01540682 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: MLN8237
DRUG: Cetuximab
RADIATION: Radiotherapy

Sponsor

Abramson Cancer Center at Penn Medicine